ULTRESA CAPSULE (DELAYED RELEASE)

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

LIPASE; PROTEASE; AMYLASE

Διαθέσιμο από:

APTALIS PHARMA CANADA ULC

Φαρμακολογική κατηγορία (ATC):

A09AA02

INN (Διεθνής Όνομα):

MULTIENZYMES (LIPASE, PROTEASE ETC)

Δοσολογία:

13800UNIT; 53400UNIT; 58800UNIT

Φαρμακοτεχνική μορφή:

CAPSULE (DELAYED RELEASE)

Σύνθεση:

LIPASE 13800UNIT; PROTEASE 53400UNIT; AMYLASE 58800UNIT

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

100

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

DIGESTANTS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0302964034; AHFS:

Καθεστώς αδειοδότησης:

CANCELLED POST MARKET

Ημερομηνία της άδειας:

2016-12-06

Αρχείο Π.Χ.Π.

_ _
_ULTRESA_
_®_
_ – Pancrelipase Capsules _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 18 _
PRODUCT MONOGRAPH
PR
ULTRESA
®
(Pancrelipase USP)
Capsule (Delayed- Release)
13,800, 20,700 and 23,000 USP units of lipase
USP
Pancreatic enzymes
A09AA02
Aptalis Pharma Canada Inc.
597 Sir-Wilfrid-Laurier Blvd.
Mont-Saint-Hilaire, Québec
Canada J3H 6C4
Date of Approval:
June 05, 2015
Submission Control No: 173148
_ _
_ULTRESA_
_®_
_ – Pancrelipase Capsules _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 18 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................11
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
CLINIC